During the three-month period, Lilly notched $11.3 billion in global revenue, surpassing the $9.92 billion that Wall Street expected. Adjusted earnings per share came in at $3.92, which also beat Wall Street estimates of $2.60 per share.
Eli Lilly and Co
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Lilly’s tirzepatide was first approved to treat type 2 diabetes and sold under the brand name Mounjaro in 2022.
In November 2023, federal officials approved the injection, sold under the brand name Zepbound, for adults with obesity or those who are overweight and also deal with weight-related medical issues such as hypertension, dyslipidemia or type 2 diabetes mellitus.
